Cancer Discovery · 2018 · 183 citations · 40 references
MedicineCancer BiologyOncologyCancer ImmunologyTumor ImmunologyTumor MicroenvironmentCancer GenomicsCancer TranscriptomicsKidney CancerMolecular Tumor ProfilingRenal Cell CarcinomaTumor Immune MicroenvironmentImmune Cell TranscriptomicsImmune Gene Expression SignaturesImmune Microenvironment GenomicsNatural Regulatory T CellsRna SequencingRna Sequencing (Rna-seq)Tumor Immune Microenvironment ProfilingTumor-associated Inflammation
Abstract By leveraging tumorgraft (patient-derived xenograft) RNA-sequencing data, we developed an empirical approach, DisHet, to dissect the tumor microenvironment (eTME). We found that 65% of previously defined immune signature genes are not abundantly expressed in renal cell carcinoma (RCC) and identified 610 novel immune/stromal transcripts. Using eTME, genomics, pathology, and medical record data involving >1,000 patients, we established an inflamed pan-RCC subtype (IS) enriched for regulatory T cells, natural killer cells, TH1 cells, neutrophils, macrophages, B cells, and CD8+ T cells. IS is enriched for aggressive RCCs, including BAP1-deficient clear-cell and type 2 papillary tumors. The IS subtype correlated with systemic manifestations of inflammation such as thrombocytosis and anemia, which are enigmatic predictors of poor prognosis. Furthermore, IS was a strong predictor of poor survival. Our analyses suggest that tumor cells drive the stromal immune response. These data provide a missing link between tumor cells, the TME, and systemic factors. Significance: We undertook a novel empirical approach to dissect the renal cell carcinoma TME by leveraging tumorgrafts. The dissection and downstream analyses uncovered missing links between tumor cells, the TME, systemic manifestations of inflammation, and poor prognosis. Cancer Discov; 8(9); 1142–55. ©2018 AACR. This article is highlighted in the In This Issue feature, p. 1047
40
Inferring tumour purity and stromal and immune cell admixture from expression data
Kosuke Yoshihara, Maria Shahmoradgoli, Emmanuel Martínez et al. · Nature Communications · 2013 · 10.7K citations · Full text
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Robert J. Motzer, Bernard Escudier, Saby George et al. · New England Journal of Medicine · 2015 · 5.9K citations · Full text
Medicine, Oncology, Pharmacotherapy +17
Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer
Gabriela Bindea, Bernhard Mlecnik, Marie Tosolini et al. · Immunity · 2013 · 4.7K citations · Full text
Medicine, Immunology, Oncology +17
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
David A. Barbie, Pablo Tamayo, Jesse S. Boehm et al. · Nature · 2009 · 4.2K citations · Full text